Stem cell therapy for myocardial infarction: Are we missing time?

Cardiology

Volumn 117, Issue 1, 2010, Pages 1-10

  Ter Horst, Kasper W ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Bone marrow; Clinical trials; Myocardial infarction; Stem cell therapy; Timing

Indexed keywords

ADENOSINE; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; MONOCYTE CHEMOTACTIC PROTEIN 3; PHOSPHATE BUFFERED SALINE; PLACEBO; REACTIVE OXYGEN METABOLITE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ANGIOGENESIS; CD34 SELECTION; CELL ADHESION; CELL DIFFERENTIATION; CELL HOMING; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG HALF LIFE; DRUG POTENCY; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; MACROPHAGE; NEUTROPHIL; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SHAM PROCEDURE; STEM CELL; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYOCARDIAL INFARCTION; TIME FACTORS; WOUND HEALING;

EID: 77957157181     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318840     Document Type: Review

References (61)

1. Smith RR, Barile L, Messina E, Marbán E: Stem cells in the heart: what's the buzz all about? I. Preclinical considerations. Heart Rhythm 2008; 5:749-757.
2. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassan ipour M, Police S, O'Su l livan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE: Cardio-myocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotech-nol 2007; 25:1015-1024.
3. Caspi O, Huber I, Kehat I, Habib M, Arbel G, Gepstein A, Yankelson L, Aronson D, Beyar R, Gepstein L: Transplantation of human embryonic stem cell-derived cardiomyo-cytes improves myocardial performance in rat hearts. J Am Coll Cardiol 2007; 50: 1884-1893.
4. Jain M, DerSimonian H, Brenner DA, Ngoy S, Teller P, Edge AS, Zawadzka A, Wetzel K, Sawyer DB, Colucci WS, Apstein CS, Liao R: Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001; 103: 1920-1927.
5. Kocher AA, Schuster MD, Szabolcs MJ, Ta-kuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardio-myocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-436.
6. Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, Sadamoto K, Horii M, Matsumoto T, Mu-rasawa S, Shibata T, Suehiro S, Asahara T: Dose-dependent contribution of CD34-pos-itive cell transplantation to concurrent vas-culogenesis and cardiomyogenesis for functional recovery after myocardial infarction. Circulation 2006; 113 : 1311-1325.
7. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baumgart-ner WW, Martin BJ, Heldman AW, Hare JM: Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005; 102:11474-11479.
8. Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagège AA: The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117:1189-1200.
9. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM: Autolo-gous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008; 29:1807-1818.
10. Schoenhard JA, Hatzopoulos AK: Stem cell therapy: pieces of the puzzle. J Cardiovasc Transl Res 2010; 3: 49-60.
11. Zhang S, Sun A, Xu D, Yao K, Huang Z, Jin H, Wang K, Z ou Y, Ge J: Impact of ti ming on efficacy and safety of intracoronary autolo-gous bone mar row stem cel ls t ranspla nt ation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials. Clin Cardiol 2009; 32: 458-466.
12. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B: Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 989-997.
13. Li RK, Mickle DA, Weisel RD, Rao V, Jia ZQ: Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury. Ann Thorac Surg 2001; 72: 1957-1963.
14. Bartunek J, Wijns W, Heyndrickx GR, Van-derheyden M: Timing of intracoronary bone-marrow-derived stem cell transplantation after ST-elevation myocardial infarction. Nat Clin Pract Cardiovasc Med 2006; 3(suppl 1):S52-S56.
15. Vandervelde S: Stem Cell-Mediated Regeneration of the Infarcted Heart: Inflammation Rules? thesis, University of Groningen, Groningen, 2005.
16. Hu X, Wang J, Chen J, Luo R, He A, Xie X, Li J: Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg 2007; 31:438-443. (Pubitemid 46329387)
17. Jiang CY, Gui C, He AN, Hu XY, Chen J, Jiang Y, Wang JA: Optimal time for mesenchymal stem cell transplantation in rats with myocardial infarction. J Zhejiang Univ Sci B 2008; 9: 630-637.
18. Hill JH, Ward PA: The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971; 133: 885-900.
19. Dreyer WJ, Michael LH, Nguyen T, Smith CW, Anderson DC, Entman ML, Rossen RD: Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. Circ Res 1992; 71: 1518-1524.
20. Ivey CL, Williams FM, Collins PD, Jose PJ, Williams TJ: Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit: evidence for a role for C5a and interleukin-8. J Clin Invest 1995; 95:2720-2728.
21. Granger DN: Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol 1988; 255: 1269-1275.
22. Patel KD, Zimmerman GA, Prescott SM, McEver RP, McIntyre TM: Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol 1991; 112:749-759.
23. Sellak H, Franzini E, Hakim J, Pasquier C: Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. Blood 1994; 83: 2669-2677.
24. Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
25. Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH, Spengler RN, Smith CW, Entman ML: Resident cardiac mast cells degranulate and release preformed TNF-a, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 1998; 98:699-710.
26. Virag JI, Murry CE: Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am J Pathol 2003; 163:2433-2440.
27. Saffitz JE: The heart; in Rubin R, Strayer DS (eds): Rubin's Pathology: Clinicopathologic Foundations of Medicine, ed 5. Philadelphia, Lippincott Williams & Wilkins, 2007, pp 427-481.
28. Sun Y, Weber KT: Infarct scar: a dynamic tissue. Cardiovasc Res 2000; 46:250-256.
29. Vandervelde S, van Luyn MJ, Tio RA, Harm-sen MC: Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol 2005; 39:363-376.
30. Wang Y, Johnsen HE, Mortensen S, Bindslev L, Ripa RS, Haack-Sørensen M, Jørgensen E, Fang W, Kastrup J: Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart 2006; 92:768-774.
31. Reinecke H, Minami E, Zhu WZ, Laflamme MA: Cardiogenic differentiation and trans-differentiation of progenitor cells. Circ Res 2008; 103:1058-1071.
32. Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A, Muskheli V Pa-bon L, Reinecke H, Murry CE: Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 2007; 21: 1345-1357.
33. Schenk S, Mal N, Finan A, Zhang M, Kied-rowski M, Popovic Z, McCarthy PM, Penn MS: MCP-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007; 25: 245-251.
34. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ: Stromal cell-derived factor-1a plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004; 110:3300-3305.
35. Vandervelde S, van Luyn MJ, Rozenbaum MH, Petersena AH, Tiob RA, Harmsen MC: Stem cell-related cardiac gene expression early after murine myocardial infarction. Cardiovasc Res 2007; 73: 783-793.
36. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS: Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703.
37. Ma J, Ge J, Zhang S, Sun A, Shen J, Chen L, Wang K, Zou Y: Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol 2005; 100:217-223.
38. Kuang D, Zhao X, Xiao G, Ni J, Feng Y, Wu R, Wang G: Stem cell factor/c-kit signaling mediated cardiac stem cell migration via activation of p38 MAPK. Basic Res Cardiol 2008; 103: 265-273.
39. O'Blenes SB, Li AW, Chen R, Arora RC, Horackova M: Engraftment is optimal when myoblasts are transplanted early: the role of hepatocyte growth factor. Ann Thorac Surg 2010; 89:829-835.
40. Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, Ganser A, Knapp WH, Drexler H: Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198-2202.
41. Blocklet D, Toungouz M, Berkenboom G, Lambermont M, Unger P, Preumont N, Stoupel E, Egrise D, Degaute JP, Goldman M, Goldman S: Myocardial homing of nonmo-bilized peripheral-blood CD34+ cells after intracoronary injection. Stem Cells 2006; 24: 333-336.
42. Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev 2006; 15: 305-313.
43. Drexler H, Meyer GP, Wollert KC: Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trial. Nat Clin Pract Cardiovasc Med 2006; 3(suppl 1):S65-S68.
44. Lutz M, Rosenberg M, Kiessling F, Eckstein V, Heger T, Krebs J, Ho AD, Katus HA, Frey N: Local injection of stem cell factor (SCF) improves myocardial homing of systemical-ly delivered c-kit + bone marrow-derived stem cells. Cardiovasc Res 2008; 77:143-150.
45. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON, Penn MS: SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myo-cytes after myocardial infarction. FASEB J 2007; 21:3197-3207. (Pubitemid 47565538)
46. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo L G, Kong D: Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008; 16:571-579.
47. Ryzhov S, Solenkova NV, Goldstein AE, Lamparter M, Fleenor T, Young PP, Greelish JP, Byrne JG, Vaughan DE, Biaggioni I, Hat-zopoulos AK, Feoktistov I: Adenosine receptor-mediated adhesion of endothelial progenitors to cardiac microvascular endo-t helia l cells. Circ Res 2008; 102 : 356-363.
48. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE: Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol 2001; 33: 907-921.
49. Becker LB: New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004; 61:461-470.
50. de Vries B, Köhl J, Leclercq WK, Wolfs TG, van Bijnen AA, Heeringa P, Buurman WA: Complement factor C5a mediates renal isch-emia-reperfusion injury independent from neutrophils. J Immunol 2003; 170: 3883-3889.
51. Guo RF, Ward PA: Role of c5a in inflamma-tor y responses. Annu Rev Immunol 2005; 23: 821-852.
52. Krugliakov PV, Sokolova IB, Amineva KhK, Nekrasova NN, Viǐde SV, Cherednichenko NV, Zaritskiǐ AIu, Semerin EN, Kisliakova TV, Polyntsev DG: The influence of mesen-chymal stem cell transplantation time on myocardial reparation in rat experimental heart failure (in Russian). Tsitologiia 2005; 47:404-416.
53. Kupatt C, Hinkel R, Lamparter M, von Brühl ML, Pohl T, Horstkotte J, Beck H, Müller S, Delker S, Gildehaus FJ, Büning H, Hatzo-poulos AK, Boekstegers P: Retroinfusion of embryonic endothelial progenitor cells attenuates ischemia-reperfusion injury in pigs: role of phophatidylinositol 3-kinase/AKT kinase. Circulation 2005; 112:I117-I122.
54. Schächinger V, Erbs S, Elsässer A, Haber-bosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süsel-beck T, Assmus B, Tonn T, Dimmeler S, Zei-her AM, REPAIR-AMI Investigators: Intra-coronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221. (Pubitemid 44427445)
55. Dill T, Schächinger V, Rolf A, Möllmann S, Thiele H, Tillmanns H, Assmus B, Dimmeler S, Zeiher AM, Hamm C: Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in p at ients at r isk for adverse remodel i ng after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 2009; 157: 541-547.
56. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Her-bots L, Sinnaeve P, Dens J, Maertens J, Rade-makers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F: Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367:113-121.
57. Gyöngyösi M, Lang I, Dettke M, Beran G, Graf S, Sochor H, Nyolczas N, Charwat S, Hemetsberger R, Christ G, Edes I, Balogh L, Krause KT, Jaquet K, Kuck KH, Benedek I, Hintea T, Kiss R, Préda I, Kotevski V, Pejkov H, Zamini S, Khorsand A, Sodeck G, Kaider A, Maurer G, Glogar D: Combined delivery approach of bone ma rrow mononuclea r stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med 2009; 6:70-81.
58. Cook DI, Gebski VJ, Keech AC: Subgroup analysis in clinical trials. Med J Aust 2004; 180 : 289-291.
59. Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD, Cardiovascular Cell Therapy Research Network: Rationale and design for TIME: a phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myo-cardial infarction. Am Heart J 2009; 158: 356-363.
60. Verfaillie C: Pluripotent stem cells. Transfus Clin Biol 2009; 16: 65-69.
61. Tokcaer-Keskin Z, Akar AR, Ayaloglu-Bu-tun F, Terzioglu-Kara E, Durdu S, Ozyurda U, Ugur M, Akcali KC: Timing of induction of cardiomyocyte differentiation for in vitro cultured mesenchymal stem cells: a perspective for emergencies. Can J Physiol Pharmacol 2009; 87:143-150.